Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › AUTL

Autolus Therapeutics

AUTL Rare disease Lead: Approved 4 Biotech Distilled articles ↓ 25 filings & releases ↓ Cash $171M (Jun 30, 2026) ↓ 4 verdicts ↓
HematologyImmunologyNeurologyOncologyRenal Cell

Market cap $341M 266.2M shares (10-Q, Aug 10, 2026) × $1.28 close Nov 6, 2026

Most recent annual filing: 2026-03-27

Catalyst timeline

10 trackedQuarter catalyst calendar →
  1. CARLYSLE SLE Ph1 interimYear-end 2026CARLYSLE SLE Ph1 interim, Year-end 2026, notable
  2. ALARIC AL Ph1 interimYear-end 2026ALARIC AL Ph1 interim, Year-end 2026, notable
  3. AUTO1/22 CARPALL readoutlate 2026AUTO1/22 CARPALL readout, late 2026, notable
  4. AUTO8 readoutYE 2026AUTO8 readout, YE 2026, notable
  5. BOBCAT MS Ph1 interim1Q 2027BOBCAT MS Ph1 interim, 1Q 2027, major
  6. BOBCAT MS Ph2 readout1Q 2027BOBCAT MS Ph2 readout, 1Q 2027, material
  7. Perceptive Note Facility manufacturing updateJan 30, 2027Perceptive Note Facility manufacturing update, Jan 30, 2027, routine
  8. CATULUS Pediatric r Ph2 toplineYear-end 2027CATULUS Pediatric r Ph2 topline, Year-end 2027, material
  9. Company cash runway corporate update4Q 2027Company cash runway corporate update, 4Q 2027, routine
  10. LUMINA LN Ph2 topline2028LUMINA LN Ph2 topline, 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

AUCATZYL

obecabtagene autoleucel · obe-cel · AUTO1
Cell Target: CD19

Capital (as filed)

Cash
$171M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$30.2M Jun 30, 2026
Operating cash flow
−$25.1M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$202M cash, runway Q2 2028 per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Autolus Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-23 Watch Autolus Therapeutics (AUTL) — Scientific Deep Dive for Obe-cel and Pipeline Products Real revenue and differentiated biology but the royalty stack and likely 2027 dilution event keep this from being a clean BUY; upgrade conditions are Q2/Q3 revenue tracking to high end of guidance or a clean BOBCAT Phase 1 biomarker readout.
  2. 2026-08-03 Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - The Dilution Gap Just Got Debt-Financed Q2 revenue up ~70% sequentially, guidance raised above prior high end, gross margin flipped from -20% to +35%, and the dilution gap was bridged with debt at ~1.3% warrant dilution rather than a punishing equity print, meeting the explicit upgrade condition set in May.
  3. 2026-08-12 Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - 55% Gross Margin, and the MS Catalyst Just Slid a Quarter Q2 gross margin printed at 55% confirming the commercial thesis, but BOBCAT MS readout slipped to Q1 2027 and the stock already ran +28%, so the margin surprise is in the price and no upgrade to clean BUY is warranted.
  4. 2026-09-09 Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - The FDA Just Blessed the n=6 FDA RMAT designation in SLE/LN directly addresses the bear-case risk of the agency rejecting a single-arm registrational path, but it is procedural not data, and the covenant test and clinical readouts still ahead keep the stance at speculative rather than clean BUY.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)